Journey Medical Corp
DERM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001867066
No open-market purchases or sales by Journey Medical Corp insiders were filed in the last 90 days; 71 institutions reported holding it in 13F filings for Q2 2026, worth $75.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 71
- 13F valueReported value at the end of Q2 2026
- $75.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding DERM, Q2 2026
No superinvestor reported holding DERM at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Journey Medical Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 5, 2025 (view filing) | May 2 | 3 days | Maraoui ClaudePresident & CEO | SSaleCommon Stock, $0.0001 par value | −4.83K | $6.84 | −$33.1K | −0.2%2.35M after | |
| May 5, 2025 (view filing) | May 2 | 3 days | Benesch JosephCFO | SSaleCommon Stock, $0.0001 par value | −2.41K | $6.84 | −$16.5K | −1.2%203.6K after | |
| May 5, 2025 (view filing) | May 2 | 3 days | Alloush RamseyCOO | SSaleCommon Stock, $0.0001 par value | −2.86K | $6.84 | −$19.5K | −0.6%504.8K after | |
| Mar 11, 2025 (view filing) | Mar 11 | Same day | Maraoui ClaudePresident & CEO | SSaleCommon Stock, $0.0001 par value | −49.3K | $5.01 | −$246.8K | −2.4%2.00M after | |
| Mar 10, 2025 (view filing) | Mar 6-7 | 4 days | Maraoui ClaudePresident & CEO | SSaleCommon Stock, $0.0001 par value | −40.5K | $5.03 | −$203.5K | −1.9%2.05M after | 2 lots |
| Mar 5, 2025 (view filing) | Mar 3-5 | 2 days | Maraoui ClaudePresident & CEO | SSaleCommon Stock, $0.0001 par value | −70.6K | $5.11 | −$360.8K | −3.3%2.09M after | 3 lots |
| Feb 24, 2025 (view filing) | Feb 21 | 3 days | Benesch JosephCFO | SSaleCommon Stock, $0.0001 par value | −1.36K | $5.19 | −$7.08K | −2.9%46.0K after | |
| Aug 1, 2024 (view filing) | Aug 1 | Same day | Benesch JosephCFO | SSaleCommon Stock, $0.0001 par value | −9.32K | $5.47 | −$51.0K | −16.5%47.3K after | |
| Jul 23, 2024 (view filing) | Jul 23 | Same day | Benesch JosephCFO | SSaleCommon Stock, $0.0001 par value | −4.05K | $5.40 | −$21.9K | −6.7%56.7K after | |
| Mar 27, 2024 (view filing) | Mar 25 | 2 days | Rosenwald Lindsay A MDDirector | PPurchaseCommon Stock, $0.0001 par value | +10.0K | $3.04 | +$30.4K | +7.4%144.2K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Journey Medical Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wasatch Advisors Inc | 2,858,930 | $20.2M | 0.13% | +725,560+34.0% | Added |
| Tang Capital Management LLC | 1,610,000 | $11.4M | 0.52% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 675,185 | $4.78M | 0.00% | −406,895−37.6% | Reduced |
| Punch & Associates Investment Management, Inc. | 536,000 | $3.79M | 0.19% | +536,000 | New |
| Pale Fire Capital SE | 528,584 | $3.74M | 0.27% | +46,597+9.7% | Added |
| Opaleye Management Inc. | 350,000 | $2.48M | 0.22% | −610,000−63.5% | Reduced |
| Summit Financial, LLC | 346,748 | $2.45M | 0.03% | −33,059−8.7% | Reduced |
| Jane Street Group, LLC | 320,021 | $2.27M | 0.00% | +320,021 | New |
| Diametric Capital, LP | 295,663 | $2.09M | 0.22% | +99,251+50.5% | Added |
| Ikarian Capital, LLC | 251,436 | $1.78M | 0.29% | 00.0% | Unchanged |